CLRB - Cellectar Biosciences - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

19.7M

Cash

5.153M

Avg Qtr Burn

-7.285M

Short % of Float

10.65%

Insider Ownership

5.16%

Institutional Own.

33.90%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Iopofosine (CLR 131) Details Cancer, Multiple myeloma, High Refractory Multiple Myeloma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Iopofosine (CLR 131) Details Cancer, Waldenstrom macroglobulinemia, Lymphoma Big Mover™ Suspected Mover™ Susp. Mover™	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Iopofosine (CLR 131) Details Cancer, B-cell lymphoma, Lymphoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Iopofosine (CLR 131) Details Cancer, B-cell lymphoma, Lymphoma, B-cell malignancies, Pediatric Sarcomas, High-grade Glioma	Phase 1b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.